LON:DNL Diurnal Group (DNL) Share Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free DNL Stock Alerts GBX 27.30 0.00 (0.00%) (As of 10/31/2022) Add Compare Share Share Today's Range 27.30▼ 27.3050-Day Range 27.30▼ 27.3052-Week Range 9.50▼ 67.90Volume145,283 shsAverage Volume483,617 shsMarket Capitalization£46.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Diurnal Group alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Diurnal Group Stock (LON:DNL)Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.Read More DNL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNL Stock News HeadlinesFebruary 6, 2024 | morningstar.comDa Nang Port Logistics JSC DNLDecember 9, 2023 | morningstar.comD&L Industries IncApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.August 23, 2023 | investing.comD&L Industries Inc (DNL)March 22, 2023 | wsj.comD&L Industries Inc.October 28, 2022 | finance.yahoo.comForm 8.3 - Diurnal Group plcAugust 30, 2022 | markets.businessinsider.comForm 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plcAugust 30, 2022 | marketwatch.comDiurnal Group Agrees to High Premium $56.5 Mln Takeover by Neurocrine BiosciencesApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.August 16, 2022 | finance.yahoo.comDiurnal Group plc (DNL.L)March 22, 2022 | proactiveinvestors.com.auAIQ boosted by deal to supply NFT marketplace in Hong KongMarch 22, 2022 | proactiveinvestors.comDiurnal drops after losses nearly double and it seeks fundingMarch 22, 2022 | proactiveinvestors.comDiurnal nosedives on need for further fundingMarch 9, 2022 | proactiveinvestors.com.auDiurnal dips as bosses give investor presentationMarch 2, 2022 | morningstar.comDiurnal Group Says Male Hypogonadism Treatment Study to Be DelayedNovember 16, 2021 | marketwatch.comDiurnal Group's Alkindi Drug Approved for Use in Children, Adolescents in SwitzerlandNovember 13, 2021 | finance.yahoo.comShareholders May Be More Conservative With Diurnal Group plc's (LON:DNL) CEO Compensation For NowOctober 11, 2021 | marketwatch.comDiurnal Group Ditest Clinical Trial Results PublishedSeptember 28, 2021 | markets.businessinsider.comHardman & Co Research : Diurnal Group (DNL): All set for three pivotal trialsSeptember 16, 2021 | markets.businessinsider.comDiurnal Group PLC : Commercial launch of Efmody in the UKSeptember 16, 2021 | finanznachrichten.deHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trialsSeptember 16, 2021 | finanznachrichten.deHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trialsSeptember 15, 2021 | finance.yahoo.comHere's Why We're Not Too Worried About Diurnal Group's (LON:DNL) Cash Burn SituationAugust 8, 2021 | markets.businessinsider.comDiurnal Group PLC : Business and Trading UpdateJuly 24, 2021 | news.yahoo.comHartwick Seminary Summer Institute of Theology to mark 30 yearsJuly 22, 2021 | news.yahoo.comFormer Wacker site manager to oversee Chattanooga's Smart Factory Institute at Volkswagen AcademySee More Headlines Receive DNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/15/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:DNL CUSIPN/A CIKN/A Webwww.diurnal.co.uk Phone+44-29-20682069FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.77 Current Ratio5.23 Quick Ratio4.16 Sales & Book Value Annual Sales£4.68 million Price / Sales9.89 Cash FlowGBX 9.70 per share Price / Cash Flow2.81 Book ValueGBX 12.70 per share Price / Book2.15Miscellaneous Outstanding Shares169,720,000Free FloatN/AMarket Cap£46.33 million OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Richard Edward Bungay A.C.A. (Age 53)ACA, B.Sc., BSc, Interim CEO, CFO, Company Sec. & Director Comp: $338kProf. Richard RossChief Scientific Officer & Exec. DirectorMr. Stewart JonesOperations DirectorMr. John Porter MBBSPh.D., Chief Medical OfficerMr. David Bevan (Age 55)Chief Bus. Officer Key CompetitorsVenture Life GroupLON:VLGECO Animal Health GroupLON:EAHCeladon PharmaceuticalsLON:CELProvexisLON:PXSAnimalcare GroupLON:ANCRView All Competitors DNL Stock Analysis - Frequently Asked Questions How have DNL shares performed in 2024? Diurnal Group's stock was trading at GBX 27.30 at the beginning of the year. Since then, DNL stock has increased by 0.0% and is now trading at GBX 27.30. View the best growth stocks for 2024 here. How were Diurnal Group's earnings last quarter? Diurnal Group plc (LON:DNL) issued its quarterly earnings results on Tuesday, September, 15th. The company reported ($4.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.70) by $2.40. What other stocks do shareholders of Diurnal Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), Cerecor (CERC), Revolution Lighting Technologies (RVLT), Spero Therapeutics (SPRO), SRC Energy (SRCI), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF) and AcelRx Pharmaceuticals (ACRX). How do I buy shares of Diurnal Group? Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DNL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diurnal Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
